Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy

Clinical Cancer Research

Volumn 16, Issue 6, 2010, Pages 1875-1883

  Sciarra, Alessandro ^a   Panebianco, Valeria ^a   Ciccariello, Mauro ^a   Salciccia, Stefano ^a   Cattarino, Susanna ^a   Lisi, Danilo ^a   Gentilucci, Alessandro ^a   Alfarone, Andrea ^a   Bernardo, Silvia ^a   Passariello, Roberto ^a   Gentile, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DYNAMIC CONTRAST ENHANCEMENT MAGNETIC RESONANCE; FALSE NEGATIVE RESULT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC ERROR;

ADENOCARCINOMA; AGED; BIOPSY; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 77949660663     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2195     Document Type: Article

References (28)

1. Seitz M, Shukla-Dave A, Bjartell A, et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009, [Epub ahead of print]55:801-14.
2. Panebianco V, Sciarra A, Osimani M, et al. 2D and 3D T2-weighted MR sequence for the assessment of neurovascular bundles changes after nerve sparing radical prostatectomy with erectile function correlation. Eur Radiol 2009;19:220-9.
3. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50: 1163-75.
4. Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006;50:738-49.
5. Rajesh A, Coakley FV, Khrhanewicz J. 3D spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol 2007;62:921-9.
6. Hricak H. MR imaging and MR spectroscopic imaging in the pretreatment evaluation of prostate cancer. Br J Radiol 2005;78:103-11.
7. Rajesh A, Coakley FV. MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin N Am 2004;12:557-79.
8. Casciani E, Gualdi G. Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 2006;31: 490-9.
9. Sciarra A, Salciccia S, Panebianco V. Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging. Eur Urol 2008;54:485-8.
10. Yuen JSP, Thng CH, Tan PH, et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004; 171:1482-6.
11. Amsellem-Ouazana D, Younes P, Conquy S, et al. Negative prostatic biopsies in patients with high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005;47: 582-6.
12. Zackrisson B, Aus G, Bergdahl S. The risk of findings focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 2004;171:1500-3.
13. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730-3.
14. Sciarra A, Autran Gomez A, Salciccia S, et al. Biopsy-derived Gleason artifact and prostate volume: experience using ten samples in larger prostates. Urol Int 2008;80:145-50.
15. Kumar R, Nayyar R, Kumar V. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/mL: a follow-up study. Urology 2008;72:859-63.
16. Sciarra A, Panebianco V, Salciccia S. Role of dynamic contrastenhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600.
17. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164:400-4.
18. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11c-choline PET/CT. Radiology 2007;244:797-806.
19. Kurhanewicz J, Vigneron DB, Hricak H, et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996;200:489-96.
20. Cirillo S, Petracchini M, Della Monica P, et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumors. Clinical Radiology 2008;63:871-9.
21. Fütterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58.
22. Wetter A, Hübner F, Lehnert T, et al. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol 2005;15: 645-52.
23. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52:1309-22.
24. Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004;172:94-7.
25. Perrotti M, Han KR, Epstein RE, et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 1999;162: 1314-22.
26. Vilanova JC, Comet J, Capdevila A, et al. The value of endorectal MR imaging to predict positive biopsies in clinically intermadiate-risk prostate cancer patients. Eur Radiol 2001;11:29-35.
27. Zakian Kl, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234: 804-14.
28. Delongchamps NB, Hass GP. Saturation biopsies for prostate cancer: current uses and future prospects. Nat Rev Urol 2009;6:645-52.